Pharmaceuticalization of Society in Context: Theoretical, Empirical and Health Dimensions
暂无分享,去创建一个
[1] G. Salmon,et al. Attention deficit hyperactivity disorder. , 2018, British journal of hospital medicine.
[2] J. Abraham. Partial progress: governing the pharmaceutical industry and the NHS, 1948-2008. , 2009, Journal of health politics, policy and law.
[3] C. Davis,et al. Drug Evaluation and the Permissive Principle , 2009, Social studies of science.
[4] B. Marshall. Sexual Medicine, Sexual Bodies and the ‘Pharmaceutical Imagination’ , 2009 .
[5] K. Throsby. The War on Obesity as a Moral Project: Weight Loss Drugs, Obesity Surgery and Negotiating Failure , 2009 .
[6] P. Conrad,et al. From Lydia Pinkham to Queen Levitra: direct-to-consumer advertising and medicalisation. , 2008, Sociology of health & illness.
[7] F. Stevenson,et al. Over-the-counter medicines: professional expertise and consumer discourses. , 2008, Sociology of health & illness.
[8] Katie J. Ward,et al. Pharma in the bedroom . . . and the kitchen. . . . The pharmaceuticalisation of daily life. , 2008, Sociology of health & illness.
[9] Kathryn L. Jones. In whose interest? Relationships between health consumer groups and the pharmaceutical industry in the UK. , 2008, Sociology of health & illness.
[10] J. Abraham. Sociology of pharmaceuticals development and regulation: a realist empirical research programme. , 2008, Sociology of health & illness.
[11] Blair T. Johnson,et al. Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration , 2008, PLoS medicine.
[12] N. Britten. Medicines and society , 2008 .
[13] Órla O’Donovan. Corporate Colonization of Health Activism? Irish Health Advocacy Organizations' Modes of Engagement with Pharmaceutical Corporations , 2007, International journal of health services : planning, administration, evaluation.
[14] C. Davis,et al. Deficits, Expectations and Paradigms in British and American Drug Safety Assessments , 2007 .
[15] John Abraham,et al. Interpellative Sociology of Pharmaceuticals: Problems and Challenges for Innovation and Regulation in the 21st Century , 2007, Technol. Anal. Strateg. Manag..
[16] S. Majumdar,et al. Drug treatments for obesity – Authors' reply , 2007, The Lancet.
[17] P. Couzigou. Drug treatments for obesity , 2007, The Lancet.
[18] N. Bjarnason,et al. Drug treatments for obesity , 2007, The Lancet.
[19] Nikolas Rose. Beyond medicalisation , 2007, The Lancet.
[20] J. Bartlett,et al. Anti-infective research and development--problems, challenges, and solutions. , 2007, The Lancet. Infectious diseases.
[21] A. Trkola,et al. Complement Lysis Activity in Autologous Plasma Is Associated with Lower Viral Loads during the Acute Phase of HIV-1 Infection , 2006, PLoS medicine.
[22] E. Martin,et al. The Pharmaceutical Person , 2006 .
[23] J. Busfield. Pills, Power, People: Sociological Understandings of the Pharmaceutical Industry , 2006 .
[24] D. Healy. The Latest Mania: Selling Bipolar Disorder , 2006, PLoS medicine.
[25] Kalman D. Applbaum,et al. Pharmaceutical Marketing and the Invention of the Medical Consumer , 2006, PLoS medicine.
[26] Christine B Phillips. Medicine Goes to School: Teachers as Sickness Brokers for ADHD , 2006, PLoS medicine.
[27] A. Kleinman,et al. The New Medical Oikumene , 2006 .
[28] D. Pritchard. Attention deficit hyperactivity disorder in children. , 2005, Clinical evidence.
[29] A. Rafalovich. Exploring clinician uncertainty in the diagnosis and treatment of attention deficit hyperactivity disorder. , 2005, Sociology of health & illness.
[30] P. Conrad. The shifting engines of medicalization. , 2005, Journal of health and social behavior.
[31] Thomas R Fleming,et al. Surrogate endpoints and FDA's accelerated approval process. , 2005, Health affairs.
[32] H. Lofgren. Pharmaceuticals and the consumer movement: the ambivalences of 'patient power'. , 2004, Australian health review : a publication of the Australian Hospital Association.
[33] B. Chabner,et al. Beyond fast track for drug approvals. , 2004, The New England journal of medicine.
[34] C. May. Medicines out of Control , 2004 .
[35] J. Powers,et al. Trends in antimicrobial drug development: implications for the future. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[36] Joe Collier,et al. Let Them Eat Prozac , 2004, BMJ : British Medical Journal.
[37] I. Crinson. The Politics of Regulation within the ‘Modernized’ NHS: The Case of Beta Interferon and the ‘Cost-Effective’ Treatment of Multiple Sclerosis , 2004 .
[38] Mauricio Castillo,et al. Neurometabolic functioning and neuropsychological correlates in children with ADHD-H: preliminary findings. , 2004, The Journal of neuropsychiatry and clinical neurosciences.
[39] D. Carpenter,et al. The political economy of FDA drug review: processing, politics, and lessons for policy. , 2004, Health affairs.
[40] Marcia Angell,et al. The Truth About the Drug Companies , 2004 .
[41] L. Stalley,et al. The Influence of the Pharmaceutical Industry , 2004 .
[42] Bruce Neal,et al. Priority medicines for Europe and the world , 2004 .
[43] Christian la Fougere,et al. The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder , 2003, Neuroscience & Biobehavioral Reviews.
[44] R. Kravitz,et al. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[45] Andrew Herxheimer,et al. Relationships between the pharmaceutical industry and patients' organisations , 2003, BMJ : British Medical Journal.
[46] B. Djulbegovic,et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review , 2003, BMJ : British Medical Journal.
[47] A. Clarke,et al. Biomedicalization: Technoscientific Transformations of Health, Illness, and U.S. Biomedicine , 2003, American Sociological Review.
[48] J. Abraham. Transnational industrial power, the medical profession and the regulatory state: adverse drug reactions and the crisis over the safety of Halcion in the Netherlands and the UK. , 2002, Social science & medicine.
[49] Alan C. Evans,et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder. , 2002, JAMA.
[50] J. Abraham,et al. Progress, Innovation and Regulatory Science in Drug Development , 2002, Social studies of science.
[51] Laurence Bervoets. [Attention deficit hyperactivity disorder in children]. , 2002, Journal de pharmacie de Belgique.
[52] J. Abraham,et al. Citizenship, Medical Expertise and the Capitalist Regulatory State in Europe , 2002 .
[53] H. Mantsch,et al. Lessons from the glitazones , 2001, The Lancet.
[54] J. Lexchin,et al. Lifestyle drugs: issues for debate. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[55] J. Collier. Regulating Medicines in Europe: Competition, Expertise and Public Health , 2001, BMJ : British Medical Journal.
[56] P. Le Courtois,et al. Lessons from the glitazones. , 2001, Lancet.
[57] R. Irwin,et al. The diagnosis and treatment of cough. , 2000, The New England journal of medicine.
[58] A. Daemmrich,et al. RISK VERSUS RISK: Decision-making Dilemmas of Drug Regulation in the United States and Germany , 2000, Science as culture.
[59] J. DiMasi,et al. Measuring the Pace of New Drug Development in the User Fee ERA , 2000 .
[60] J. Abraham,et al. The therapeutic nightmare: the battle over the world's most controversial sleeping pill , 1999 .
[61] A. R. Miller. ‘Lifestyle’ drugs , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[62] D. Bramble. Attention deficit hyperactivity disorder in children , 1998, BMJ.
[63] Myron Genel,et al. Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents , 1998 .
[64] J. Abraham,et al. International Comparative Analysis and Explanation in Medical Sociology: Demystifying the Halcion Anomaly , 1998 .
[65] R. Barkley. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. , 1997, Psychological bulletin.
[66] R. Temple,et al. Approval of new drugs in the United States. Comparison with the United Kingdom, Germany, and Japan. , 1996, JAMA.
[67] H. Rothstein. Science, Politics and the Pharmaceutical Industry , 1996 .
[68] M. Schweitzer,et al. Is there a U.S. Drug Lag? The Timing of New Pharmaceutical Approvals in the G-7 Countries and Switzerland , 1996, Medical care research and review : MCRR.
[69] J. Abraham. The production and reception of scientific papers in the academic-industrial complex: the clinical evaluation of a new medicine. , 1995, The British journal of sociology.
[70] J. Abraham. Distributing the Benefit of the Doubt: Scientists, Regulators, and Drug Safety , 1994 .
[71] J. Abraham. Bias in Science and Medical Knowledge: The Opren Controversy , 1994, Sociology.
[72] L. Henderson. On the Social System , 1993 .
[73] Peter Conrad,et al. Deviance and Medicalization , 1992 .
[74] Peter Conrad,et al. Medicalization and Social Control , 1992 .
[75] P. M. Terry,et al. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. , 1991, The Journal of infectious diseases.
[76] Rein Vos,et al. Drugs Looking for Diseases , 1991, Developments in Cardiovascular Medicine.
[77] Judith M. Rumsey,et al. Cerebral glucose metabolism in adults with hyperactivity of childhood onset. , 1990 .
[78] G. Canino,et al. Impairment in the epidemiological measurement of childhood psychopathology in the community. , 1990, Journal of the American Academy of Child and Adolescent Psychiatry.
[79] D. Rothman,et al. New rules for new drugs: the challenge of AIDS to the regulatory process. , 1990, The Milbank quarterly.
[80] M. Dessens-Kroon,et al. INCREASED TETRACYCLINE RESISTANCE IN GONOCOCCI IN THE NETHERLANDS , 1989, The Lancet.
[81] Michael Bury,et al. Tranquillisers as a Social Problem , 1988 .
[82] John E. Chubb. The Political Economy of Federalism , 1985, American Political Science Review.
[83] W. Fitzgerald. Corporate Crime in the Pharmaceutical industry , 1984 .
[84] I. K. Zola,et al. Medicine as an Institution of Social Control , 1972, The Sociological review.
[85] E. Freidson. The Profession of Medicine , 1923 .